Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
37,972,605
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
35,563,534
-
Shares change
-
-839,079
-
Total reported value, excl. options
-
$677,471,610
-
Value change
-
-$16,146,542
-
Put/Call ratio
-
0%
-
Number of buys
-
74
-
Number of sells
-
62
-
Price
-
$19.05
Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) as of Q3 2022
As of 30 Sep 2022 iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) had 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 35,563,534 shares of stock of the company.
Largest 10 holders included RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., MPM ASSET MANAGEMENT LLC, BOXER CAPITAL, LLC, STATE STREET CORP, BVF INC/IL, VANGUARD GROUP INC, BIOIMPACT CAPITAL LLC, CITADEL ADVISORS LLC, and TANG CAPITAL MANAGEMENT LLC.
This table shows 131 institutional shareholders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.